Abstract
Recent developments in biotechnological techniques such as protein purification and recombinant DNA technology have led to the production of many commercial protein- and peptide-based drugs. Although the intravenous route is the preferred mode of protein drug delivery, it is associated with pain, cost, and sterility concerns. These complications can be avoided with minimally invasive microneedle (MN)-mediated transdermal drug delivery to provide better patient compliance. Currently, various formulation and microfabrication techniques are being developed to facilitate MN-mediated protein drug delivery. The design of MNs primarily relies on the heterogeneous and viscoelastic property of the skin. Presently, several MN brands have been successfully marketed and others are actively undergoing clinical trials to confirm their efficacy in the delivery of drug candidates. This chapter mainly highlights the latest developments and limitations in MN-mediated protein and peptide drug delivery. The proposed mechanism of entry of drugs administered via MN into blood circulation also has been discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
